<span item_type="fundamental" item_id="7244731b1178c0a88e7476af6748ab05" counter_id="ST/US/FOXO" env="prod"></span><span item_type="announcement" item_id="648659083564093441" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 5.168 M.</p><p>EPS: As of FY2026 Q1, the actual value is USD 0.</p><p>EBIT: As of FY2026 Q1, the actual value is USD 696.28 K.</p><p></p><h3>Segment Revenue</h3><h4>Healthcare Segment</h4><p>Net revenues for the three months ended March 31, 2026, were $4,798,551, an increase of $1,637,120 (52%) from $3,161,431 for the same period in 2025, primarily due to increased swing-bed patient services.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span></p><h4>Life Science Services Segment</h4><p>Net revenues were $361,250 for the three months ended March 31, 2026, with no comparable revenue in the prior period as this segment commenced operations on September 19, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span></p><h4>Labs Segment</h4><p>Net revenues decreased by -$4,103 (-48%) to $4,386 for the three months ended March 31, 2026, from $8,489 for the same period in 2025, primarily consisting of royalty income from Illumina, Inc.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span></p><h4>Total Net Revenues</h4><p>Total net revenues for the three months ended March 31, 2026, were $5,168,036, an increase of $1,998,116 (63.03%) from $3,169,920 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span></p><h3>Operational Metrics</h3><h4>Healthcare Segment</h4><p>Operating expenses were -$4,504,850 for the three months ended March 31, 2026, compared to -$4,010,379 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>Segment income was $296,914 for the three months ended March 31, 2026, a significant improvement from a loss of -$844,598 in the prior year, driven by increased net revenues.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>Noncontrolling interest was $3,213 for the three months ended March 31, 2026, compared to $4,350 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span></p><h4>Life Science Services Segment</h4><p>Operating expenses were -$218,834 for the three months ended March 31, 2026, with no comparable prior period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>Segment income was $142,416 for the three months ended March 31, 2026, with no comparable prior period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span></p><h4>Labs Segment</h4><p>Operating expenses were -$36,756 for the three months ended March 31, 2026, compared to -$31,494 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>The segment loss increased to -$32,370 for the three months ended March 31, 2026, from a loss of -$23,005 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span></p><h4>Overall Operating Costs and Profitability</h4><p>Direct costs of revenues were $2,534,213 for the three months ended March 31, 2026, compared to $1,903,936 for the same period in 2025, representing 49% and 60% of net revenues, respectively.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>Research and development expenses were $35,550 for the three months ended March 31, 2026, compared to $30,000 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>Selling, general and administrative expenses were $2,875,124 for the three months ended March 31, 2026, compared to $2,764,086 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>Loss from operations improved significantly to -$276,851 for the three months ended March 31, 2026, from -$1,546,980 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>Interest expense was -$973,135 for the three months ended March 31, 2026, compared to -$889,792 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>Net loss attributable to FOXO Technologies Inc. was -$1,451,973 for the three months ended March 31, 2026, compared to -$616,458 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>Adjusted EBITDA improved to -$399,691 for the three months ended March 31, 2026, from -$1,669,629 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span></p><h3>Cash Flow</h3><p>Net cash used in operating activities was -$577,898 for the three months ended March 31, 2026, an improvement from -$1,337,591 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>Net cash used in investing activities was -$3,995 for the three months ended March 31, 2026, compared to $0 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>Net cash provided by financing activities was $440,336 for the three months ended March 31, 2026, compared to $1,286,230 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>Cash and cash equivalents were $65,896 as of March 31, 2026, a decrease from $207,453 as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span></p><h3>Key Financial Position Metrics</h3><p>Working capital deficit was -$27,074,932 as of March 31, 2026, compared to -$25,546,280 as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>Total debt (net of discounts) was $8,609,877 as of March 31, 2026, compared to $7,292,040 as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>Goodwill remained stable at $27.8 million as of March 31, 2026, compared to December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>Intangible assets, net, were $9,777,041 as of March 31, 2026, compared to $9,770,969 as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>Total stockholders’ equity was $9,636,114 as of March 31, 2026, a decrease from $11,076,300 as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span></p><h3>Strategic Summary and Outlook</h3><p>FOXO Technologies Inc. plans to expand its Healthcare segment through additional facility acquisitions and service expansion at its BSF campus.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>The Life Science Services segment aims for growth via organic expansion and complementary acquisitions, while the Labs segment is exploring commercialization opportunities for its epigenetic biomarker technology, including partnerships or a potential sale.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span>The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and insufficient operating cash flow, and plans to submit a new reverse stock split proposal after restructuring with institutional investors to address capital needs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1812360/000149315226023461/form10-q.htm"></span></p>

FOXO Tech | 10-Q: FY2026 Q1 Revenue: USD 5.168 M